ArticleFrontiers in cellular and infection microbiology2026
A computational pipeline to discover potential cross-reactive antibodies: a case study on coronavirus.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cross-reactive antibody (crAb), which recognizes conserved viral epitopes across diverse strains, has emerged as powerful tools for diagnostics, therapeutic targeting, and pandemic preparedness. Yet conventional crAb discovery primarily relies on hybridoma technology and phage display which are time-consuming and labor-intensive. Methods: Here, we present an integrative computational pipeline that leverages conformational epitope prediction and epitope immunogenic similarity analysis to compute cross-reactive epitopes, so as to prioritize potential crAbs undisclosed before. Results: Taking coronavirus as an example, we demonstrate that this pipeline successfully predicted candidate crAbs for five coronavirus antigens, including SARS-CoV-2 variants (WT, Beta, Omicron B.1, XBB.1.5) and one SARS-CoV variant. Out of Top20 predicted candidates, 45% were validated in CoV-AbDab as cross-reactive across coronavirus variants, including experimentally confirmed crAbs such as P17 (IC Discussion: Though in pilot-study, this pipeline might serve as a scalable and efficient strategy for rapidly prioritizing potential crAbs in research of infectious disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.